Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease

Katelyn Paz, Ryan Flynn, Jing Du, Stacey Tannheimer, Amy J. Johnson, Shuai Dong, Anne Katrien Stark, Klaus Okkenhaug, Angela Panoskaltsis-Mortari, Peter T. Sage, Arlene H. Sharpe, Leo Luznik, Jerome Ritz, Robert J. Soiffer, Corey S. Cutler, John Koreth, Joseph H. Antin, David B. Miklos, Kelli P. MacDonald, Geoffrey R. HillIvan Maillard, Jonathan S. Serody, William J. Murphy, David H. Munn, Colby J Feser, Michael Zaiken, Bart Vanhaesebroeck, Laurence A. Turka, John C. Byrd, Bruce R Blazar

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Chronic graft-versus-host disease (cGVHD) is a leading cause of morbidity and mortality following allotransplant. Activated donor effector T cells can differentiate into pathogenic T helper (Th)-17 cells and germinal center (GC)–promoting T follicular helper (Tfh) cells, resulting in cGVHD. Phosphoinositide-3-kinase-δ (PI3Kδ), a lipid kinase, is critical for activated T cell survival, proliferation, differentiation, and metabolism. We demonstrate PI3Kδ activity in donor T cells that become Tfh cells is required for cGVHD in a nonsclerodermatous multiorgan system disease model that includes bronchiolitis obliterans (BO), dependent upon GC B cells, Tfhs, and counterbalanced by T follicular regulatory cells, each requiring PI3Kδ signaling for function and survival. Although B cells rely on PI3Kδ pathway signaling and GC formation is disrupted resulting in a substantial decrease in Ig production, PI3Kδ kinase-dead mutant donor bone marrow–derived GC B cells still supported BO cGVHD generation. A PI3Kδ-specific inhibitor, compound GS-649443, that has superior potency to idelalisib while maintaining selectivity, reduced cGVHD in mice with active disease. In a Th1-dependent and Th17-associated scleroderma model, GS-649443 effectively treated mice with active cGVHD. These data provide a foundation for clinical trials of US Food and Drug Administration (FDA)–approved PI3Kδ inhibitors for cGVHD therapy in patients.

Original languageEnglish (US)
Pages (from-to)1820-1830
Number of pages11
JournalAmerican Journal of Transplantation
Issue number6
StatePublished - Jun 2019

Bibliographical note

Funding Information:
This work was supported by the National Institutes of Health grants P01 AI 056299, P01 CA 142106, and T32 CA009138. Thank you to Dr. Christophe Queva for providing comments and edits.


  • basic (laboratory) research/science
  • graft-versus-host disease (GVHD)
  • immunobiology
  • immunosuppressant - other


Dive into the research topics of 'Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease'. Together they form a unique fingerprint.

Cite this